Matinas BioPharma Holdings, Inc. (MTNB): Nasdaq/NYSE listing notice — Matinas BioPharma receives NYSE American deficiency notice for low price; must cure by Mar 2024

Matinas BioPharma Holdings, Inc.

Received NYSE American deficiency letter for non-compliance with Section 1003(f)(v) due to 30-day avg closing price below $0.20.
Must demonstrate sustained price improvement or effect reverse stock split by March 21, 2024 to regain compliance.
Common stock continues trading on NYSE American under symbol MTNB; no immediate delisting.
Company is actively engaging with Exchange and developing plans to cure within the cure period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

Exchange: nyse american
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 1003(f)(v), 1009

Exact text from the filing

September 21, 2023, Matinas Biopharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American” or the “Exchange”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide due to its shares of common stock selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. The Letter has no immediate effect on the listing or tr

View on SEC.gov

Browse all listing & compliance notices →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-033498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.